AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)
Phase 3
Completed
- Conditions
- Locally Advanced Cervical Cancer
- Interventions
- Biological: DurvalumabRadiation: external beam radiation therapy (EBRT) + brachytherapy
- First Posted Date
- 2019-02-05
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 770
- Registration Number
- NCT03830866
- Locations
- 🇨🇳
Research Site, Taoyuan City, Taiwan
A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
Phase 1
Active, not recruiting
- Conditions
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Interventions
- First Posted Date
- 2019-01-28
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 175
- Registration Number
- NCT03819465
- Locations
- 🇹🇭
Research Site, Hat Yai, Thailand
A Disease Registry of Patients With Mantle Cell Lymphoma
Completed
- Conditions
- Mantle Cell Lymphoma
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 229
- Registration Number
- NCT03816683
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
An Open-label Study to Assess Safety and Efficacy of SZC in Paediatric Patients With Hyperkalaemia
Phase 3
Recruiting
- Conditions
- Hyperkalaemia
- Interventions
- Drug: Sodium Zirconium Cyclosilicate (SZC) Reduced Dose LevelDrug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 1 (DL1)Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 2 (DL2)Drug: Sodium Zirconium Cyclosilicate (SZC) Dose Level 3 (DL3)Drug: Sodium Zirconium Cyclosilicate (SZC) Dose During 28 Day Maintenance Phase
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT03813407
- Locations
- 🇬🇧
Research Site, Nottingham, United Kingdom
A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Heart Failure
- Interventions
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2021-04-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 12
- Registration Number
- NCT03804645
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
Assessment of Asthma Control Level in Primary Care Setting in Malaysia
Completed
- Conditions
- Asthma Control Level
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2019-05-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1011
- Registration Number
- NCT03804632
- Locations
- 🇲🇾
Research Site, Kuala Terengganu, Terengganu, Malaysia
A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Japanese Healthy Participants With Single and Multiple Ascending Dose Administration
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 28
- Registration Number
- NCT03801967
- Locations
- 🇬🇧
Research Site, Harrow, United Kingdom
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer
Phase 3
Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Other: PlaceboProcedure: Surgery
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2025-06-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 825
- Registration Number
- NCT03800134
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
First Real-world Data on Unresectable Stage III NSCLC Patients Treated With Durvalumab After Chemoradiotherapy
Completed
- Conditions
- NSCLC
- First Posted Date
- 2019-01-10
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1156
- Registration Number
- NCT03798535
- Locations
- 🇬🇧
Research Site, Stoke on Trent, United Kingdom
Benralizumab Pregnancy Exposure Study
Terminated
- Conditions
- Asthma
- Interventions
- Drug: Benralizumab-exposureDrug: Exposure to other asthma medications
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 299
- Registration Number
- NCT03794999
- Locations
- 🇺🇸
Research Site, San Diego, California, United States
© Copyright 2025. All Rights Reserved by MedPath